Disease Overview：Pancreatic Cancer（PC）
Pancreatic cancer is a highly aggressive malignancy arising from the exocrine or endocrine cells of the pancreas, with pancreatic ductal adenocarcinoma (PDAC) accounting for over 90% of cases. Due to its deep anatomical location and nonspecific early symptoms—such as weight loss, jaundice, abdominal pain, and new-onset diabetes—diagnosis often occurs at advanced stages. Five-year survival remains low, particularly for locally advanced or metastatic disease, underscoring the critical importance of precise staging, multidisciplinary tumor board evaluation, and timely intervention. Treatment modalities include surgical resection (e.g., Whipple procedure or distal pancreatectomy), neoadjuvant/adjuvant chemotherapy (e.g., FOLFIRINOX or gemcitabine/nab-paclitaxel), radiation therapy—including stereotactic body radiotherapy (SBRT) and intensity-modulated radiotherapy (IMRT)—and emerging options like irreversible electroporation (IRE) and targeted molecular therapies for select biomarker-positive patients.
China offers compelling advantages for international patients seeking pancreatic cancer care. Leading oncology centers—such as Peking Union Medical College Hospital, Fudan University Shanghai Cancer Center, and Sun Yat-sen University Cancer Center—maintain internationally accredited tumor boards, employ surgeons with high-volume pancreatic resection experience, and utilize state-of-the-art imaging (3T MRI, PET-CT), robotic-assisted surgery (da Vinci Xi), and real-time intraoperative ultrasound. Clinical outcomes align closely with global benchmarks: five-year survival after R0 resection exceeds 25% in high-volume centers, supported by robust data registries and peer-reviewed publications. Crucially, comprehensive treatment—including diagnostics, surgery, chemotherapy cycles, and supportive care—is typically 40–60% more cost-effective than in the US or Western Europe, without compromising evidence-based protocols or regulatory oversight.
As a dedicated medical tourism agency, we facilitate seamless access to these resources for international patients: verifying hospital credentials, coordinating appointments with specialist oncologists and surgeons, arranging visa support and accommodation, providing transparent itemized pricing in advance, and offering bilingual case management throughout diagnosis, treatment, and follow-up.
Pancreatic Cancer: treatment in China helps patients compare specialist hospitals, initial assessment steps and estimated costs that may vary by city, institution and clinical condition.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: Pancreatic Cancer (Oncology Department)
Non-Surgical / Medical Management
*Indicated for unresectable, metastatic, or medically inoperable disease; requires histopathological confirmation and staging (CT/MRI + CA19-9).*
- •First-line systemic therapy (FOLFIRINOX or Gemcitabine + Nab-paclitaxel):
- Supportive care (antiemetics, growth factors, hydration): $180–$320/cycle - Monitoring labs (CBC, LFTs, renal panel, CA19-9): $110–$160/cycle - Imaging (contrast-enhanced CT/MRI every 2 cycles): $480–$720/study
- •Palliative radiotherapy (SBRT or conventional EBRT):
- Fractionated course (15–25 fractions): $1,800–$3,100
- •Symptom control (biliary stenting, pain management):
- Celiac plexus neurolysis (CT-guided): $850–$1,200
Surgical / Interventional Options
*Eligibility: Resectable (no distant mets, no SMA/CHA encasement >180°, no portal vein invasion requiring reconstruction), ECOG ≤2, adequate cardiac/pulmonary reserve.*
- •Preoperative workup (mandatory):
- Cardiopulmonary evaluation (EKG, echo, PFTs if indicated): $290–$410 - Nutritional assessment + albumin/prealbumin: $65
- •Surgical procedures:
- Distal pancreatectomy ± splenectomy: $6,400–$9,300 - Total pancreatectomy: $9,100–$13,500 - Intraoperative ultrasound + frozen section: $380
- •Post-op pathology + molecular testing (KRAS/NRAS/BRAF, MSI, NTRK): $450–$890
Special/Complex Condition Management
- •Borderline resectable disease (with vascular abutment): Neoadjuvant chemoRT (FOLFIRINOX × 4 cycles + concurrent RT): $14,200–$18,500 total
- •Locally advanced unresectable: Stereotactic body radiotherapy (SBRT) + gemcitabine maintenance: $10,800–$13,600
- •BRCA1/2-mutated metastatic disease: PARP inhibitor (Olaparib) maintenance post-platinum: $2,100/month (first-line approved in China per NMPA)
- •Periampullary adenocarcinoma with duodenal involvement: Extended Whipple + intraoperative radiation (IORT): $15,400–$19,800
Quick Selection Guide
- •Fit, resectable patient (<75 y, no major comorbidities): Whipple + adjuvant gemcitabine/capecitabine — optimal survival benefit; total cost ~$11,500–$15,200.
- •Unresectable locally advanced, good PS: Neoadjuvant FOLFIRINOX → reassessment → SBRT if conversion — balances efficacy and toxicity; ~$16,000–$18,500.
- •Metastatic, elderly (>75 y) or frail: Gemcitabine monotherapy + best supportive care — lower toxicity, median cost $4,800–$7,200 over 4–6 months.
- •Budget-constrained (<$5,000): Palliative biliary stenting + symptom-directed RT + oral capecitabine — focuses on QoL; total ~$4,100–$4,900.
- •BRCA+ metastatic: Platinum-based chemo → olaparib maintenance — targeted, durable response; first-year cost ~$28,000 (includes genetic testing + drug).
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Pancreatic Cancer Medical Vacation Packages
Curated transparent all-inclusive packages combining Pancreatic Cancer treatment with China top medical destinations:
